Status:
COMPLETED
Early Administration of Heparin At FMC for PPCI of STEMI Patients
Lead Sponsor:
Renmin Hospital of Wuhan University
Collaborating Sponsors:
Xiangyang Central Hospital
The Central Hospital of Enshi Tujia And Miao Autonomous Prefecture
Conditions:
STEMI
Primary PCI
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
Heparin is the first choice of anticoagulation drug for primary PCI of STEMI patients. However, the priority of use of hepairn in first medical contact or in Cathlab has not yet studied. Previous stud...
Detailed Description
This study will recruit 944 STEMI patients undergoing primary PCI with the symptom onset within 12 hours in 36 hospitals in Hubei Province, China. The patients will be 1:1 randomly assigned to the int...
Eligibility Criteria
Inclusion
- STEMI patient; Symptom onset in 12 hours; Intended to perform PPCI
Exclusion
- Active bleeding; Life expectancy less than 1 year; History of heparin-induced thrombocytopenia; Mechanical complication of MI (VSR, acute MR); History of CABG; On Coagulation drugs; CPR before randomization; Pregnant or lactating woman.
Key Trial Info
Start Date :
July 20 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 20 2024
Estimated Enrollment :
1145 Patients enrolled
Trial Details
Trial ID
NCT05329155
Start Date
July 20 2022
End Date
August 20 2024
Last Update
March 27 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Renmin Hospital of Wuhan university
Wuhan, Hubei, China, 430000